

Researcher Profile for Webpage

Name:	Chen Ming-Huang	Date: (YYYY/MM/DD):	2020/6/9	
Department:	Department of Oncology	Position:	Attending physician	
Email:	mhchen9@vghtpe.gov.tw	Contact #:	8#1225	
Education:	PhD, National Yang-Ming Hospital.			
Experience:	<p>2020, The director of center for immune-oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)</p> <p>2017-present Associate Professor, National Yang-Ming University, Taiwan</p> <p>2017, Visitor, National Cancer Center, Tokyo, Japan</p> <p>2011, Visitor, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland (USA)</p>			
Research Interests: (Key words)	Gastrointestinal tumor, cholangiocarcinoma, immune biomarker and immune microenvironment, clinical trial			
Selected Publications (in recent 5 yr):	<ol style="list-style-type: none"> Title: <i>PRKDC</i>: New Biomarker and Drug Target for Checkpoint Blockade Immunotherapy. Tan KT, Yeh CN, Chang YC, Cheng JH, Fang WL, Yeh YC, Wang YC, Hsu DSS, Wu CE, Lai JI, Chang PMH, Chen MH, Lu ML, Chen SJ, Chao Y, Hsiao M, Chen MH. <i>J Immunother Cancer</i>. 2020 Mar;8(1):e000485 (corresponding author) Title: Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response. Pan YR, Wu CE, Wang YC, Yeh YC, Lu ML, Hung YP, Chao Y, Yeh DW, Lin CH, Hsieh JCH, Chen MH[#] and Chun-Nan Yeh[#]. Accepted by <i>Clinical & Translational Immunology</i> (co-corresponding author). Title: Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer. Chen MH, Chang SC, Lin PC, Yang SH, Lin CC, Lan YT, Lin HH, Lin CH, Lai JI, Liang WY, Lu ML, Yang MH, Chao Y. Oncologist. 2019 Dec;24(12):1534-1542. (First author and corresponding author) Title: An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas. Chen MH, Chou WC, Hsiao CF, Jiang SS, Tsai HJ, Liu YC, Hsu C, Shan YS, Hung YP, Hsieh CH, Chiu CH, Liu TC, Cho SF, Liu TW, Chao Y. <i>Oncologist</i>. 2020 May;25(5):e782-e788. ((First author and corresponding author) Title: ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients. Chen MH, Weng JJ, Cheng CT, Wu RC, Huang SC, Wu CE, Chung YH, Liu CY, Chang MH, Chen MH, Chiang KC, Yeh TS, Su Y, Yeh CN. <i>Clin Cancer Res</i>. 2016 Aug 15;22(16):4225-35.(First author) 			
Names of Lab members:	Lu Meng-Lun, Hung Ya-chi.			